AACP
CLYM

Advantage Alpha Capital Partners’s Climb Bio CLYM Stock Holding History

Advantage Alpha Capital Partners’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-48,169
Closed -$245K – 181
2024
Q3 		$245K Buy
+48,169
New +$341K 0.06% 165

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Advantage Alpha Capital Partners's CLYM Position: Q4 2024 in Review

Advantage Alpha Capital Partners sold out of Climb Bio (CLYM) in Q4 2024, closing a stake of 48,169 shares — an estimated $245K sold.

Advantage Alpha Capital Partners first reported a position in CLYM in Q3 2024 and held it in 1 quarter. The position peaked at $245K in Q3 2024. 80 funds tracked by Wall St. Rank hold CLYM as of Q4 2024.

  • Advantage Alpha Capital Partners reported no remaining Climb Bio position as of Q4 2024 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 48,169 Climb Bio shares in Q4 2024, an estimated $245K.
  • Advantage Alpha Capital Partners first reported a position in Climb Bio in Q3 2024 and held it in 1 quarter.
  • Advantage Alpha Capital Partners's Climb Bio position peaked at $245K in Q3 2024.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q4 2024.

Based on Advantage Alpha Capital Partners's 13F filing for Q4 2024, filed 11 Feb 2025.